Soluble CD73 in plasma of metastatic breast cancer patients tends to increase after radiotherapy treatment, while its blockade reduces the irradiated tumor volume and, if combined with CTLA-4 blockade, inhibits lung metastases in a mice model (Wennerberg et al., 2020). Here, NT5E is linked to breast cancer.